Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

Publication

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

Journal Paper/Review - Apr 7, 2022

König D P, Scharl Sylvie, Vuong D, Guckenberger M, Furrer Katarzyna, Opitz Isabella, Weder W, Rothschild S I, Ochsenbein A, Zippelius A, Addeo Alfredo, Mark M, Eboulet E I, Hayoz S, Thierstein S, Betticher D C, Ris H-B, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

Pless, M

Früh, M